Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Testosterone therapy aims to treat hormone deficiencies and various conditions safely and effectively, but requires careful patient monitoring due to potential side effects.

This article reviews the historical development of finasteride's approval for benign prostatic hyperplasia and discusses a trial that found decreased low-grade prostate cancer incidence but increased high-grade prostate cancer, with differing expert opinions on its use for cancer prevention.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

This review discusses the potential severe consequences of androgenic alopecia, including its association with psychosocial distress and an increased risk for certain diseases, and highlights the need for comprehensive medical evaluation.

This study identified 8-hydroxy germacrene B from Curcuma aeruginosa as a highly potent in-vitro 5-alpha reductase inhibitor with significant anti-androgenic activity, while exhibiting mild cytotoxicity on prostate cancer cells without affecting human dermal papilla cells at tested concentrations.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This collection of articles explores advancements in reproductive technologies for domestic dogs and cats, highlighting improvements like finasteride treatment for BPH in dogs and a rapid freezing method for cat sperm that enhance fertility preservation and genetic resource banking.

This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.

This study suggested that long-term finasteride treatment for BPH patients may induce neuroendocrine activity in the prostate, potentially increasing the risk of developing aggressive prostate cancer.

This study found that higher baseline expression of SRD5A2 in prostate tissue was associated with a better response to finasteride in men with benign prostatic hyperplasia.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

Hair loss can be an early sign of prostate enlargement.

This editorial comment discusses previous studies on finasteride's impact on prostate cancer development and provides no new research findings.

This editorial comment discusses previous studies on finasteride's impact on prostate cancer development and provides no new research findings.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

A new compound was made that might help treat diseases related to male hormones.

The review discusses the diverse roles of WNT10B in mammary gland development, immune function, and its potential implications in cancer and regenerative processes, with no new experimental results.

This review discusses the structure, expression, regulation, and potential functions of the nuclear receptor coactivator NcoA4 in cancerous and non-cancerous pathologies, but reports no new results.

This review found substantial data suggesting that heavy metals may influence tumor development and progression in cancers such as breast, lung, prostate, and gastric, though noted limitations and gaps in research data require further investigation.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

This study observed that intrauterine and early postnatal exposure to finasteride affected prostatic development in Mongolian gerbils, with significant sex-based differences, particularly higher alterations in female prostates.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

Finasteride safely treats enlarged prostate and male-pattern baldness.

Finasteride effectively treats hair loss and prostate issues by blocking a specific enzyme.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

This article explores the historical development and evolution of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), emphasizing advancements in safety and technology, and reports no new clinical results.

This review discusses the development and potential applications of organoids for human disease modeling and regenerative medicine but reports no new experimental results.

This review discusses the development and potential therapeutic applications of steroid sulfatase inhibitors for hormone-dependent disorders and cognitive dysfunction, reporting no new clinical results.

This review explores prostate cancer risk factors, screening, treatment, and potential roles of selenium and 5-alpha reductase inhibitors in risk reduction but presents no new clinical data.